PRN: Global Lupus Therapeutic Market (Anti-inflammatory drugs, Corticosteroids, BLyS-specific inhibitors, Biologicals & Others) 2017-2021 - Research and Markets

12/giu/2017 17:30:15 PR Newswire Turismo Contatta l'autore

Questo comunicato è stato pubblicato più di 1 anno fa. Le informazioni su questa pagina potrebbero non essere attendibili.

Global Lupus Therapeutic Market (Anti-inflammatory drugs, Corticosteroids, BLyS-specific inhibitors, Biologicals & Others) 2017-2021 - Research and Markets


DUBLIN, June 12, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Lupus Therapeutic Market 2017-2021" report to their offering.


The global lupus therapeutic market to grow at a CAGR of 9.74% during the period 2017-2021.

The report covers the present scenario and the growth prospects of the global lupus therapeutic market for 2017-2021. To calculate the market size, the report considers both generic and branded drug market. Only one drug is approved specifically for the treatment of lupus disorders and the majority of other drugs are off-label based on symptoms. Due to a strong pipeline, the market is expected for more approved drugs for lupus disorders in future. The report also includes a discussion of the Key vendors operating in this market.

The latest trend gaining momentum in the market is regenerative therapeutic technologies. The management of lupus using regenerative medicines is increasing, and many vendors are focusing on the development of regenerative medicines. The role of regenerative medicines in autoimmune disease is not explored completely. The recent studies showed that immunomodulation and suppression could be achieved through cellular interaction between therapeutic cells and the individual's immune system, including anti-inflammatory T-cell responses.

According to the report, one of the major drivers for this market is high prevalence rate. Lupus is one of the major autoimmune diseases that is associated with multiple symptoms like pain, extreme fatigue, hair loss, cognitive issues, and physical impairments, which disturbs every aspect of individual's lives.

Further, the report states that one of the major factors hindering the growth of this market is complexity of disease. Lupus is associated with multiple symptoms, which increases the complexity in individuals for diagnosis, treatment, and overall management.

Key vendors

  • F.Hoffmann-La Roche
  • GlaxoSmithKline
  • Medlmmune
  • Pfizer

Other prominent vendors

  • ADMA Biologics
  • Amgen
  • Anthera Pharmaceuticals
  • Bayer HealthCare
  • Biogen
  • Biotest
  • Bristol-Myers Squibb
  • Celgene
  • Immunomedics
  • Kedrion Biopharma
  • LFB Group
  • Merck
  • Novartis
  • Shire
  • Takeda Pharmaceuticals
  • UCB

Key Topics Covered:

Part 01: Executive summary

Part 02: Scope of the report

Part 03: Research Methodology

Part 04: Introduction

Part 05: An overview of lupus disease

Part 06: Market landscape

Part 07: Pipeline landscape

Part 08: Market segmentation by drug class

Part 09: Geographical segmentation

Part 10: Decision framework

Part 11: Drivers and challenges

Part 12: Market trends

Part 13: Vendor landscape

Part 14: Key vendor analysis

Part 15: Appendix

For more information about this report visit

Media Contact:

Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716


blog comments powered by Disqus è un servizio offerto da Factotum Srl